Talimogene Laherparepvec in Peritoneal Surface Malignancies - Clinical Trial

What is the Purpose of this Study?

If you choose to join this study you will:
-Go through a screening period which will last about 4 weeks
-Have a port placed in your stomach that will be used to give the study drug
-Receive the study drug on Day 1 and Day 22 of Cycle 1, and Day 1 of Cycles 2, 3, and 4
-Cycle 1 is 5 weeks long, and cycles 2-4 are two weeks long
-Have bloodwork done every week of Cycle 1 and on Day 1 of all other cycles

What is the Condition Being Studied?

Peritoneal Cancer

Who Can Participate in the Study?

Adults who:
-Have been diagnosed with GI, ovarian, fallopian, or peritoneal cancers
-Have had at least 1 treatment for their cancer already
-Do not take any medications for herpes infection

For more information about who can be in this study, please contact the study team.

What is Involved?

We are doing this study to see if the study drug (Talimogene Laherparepvec) can help slow down the growth of your tumor or make it smaller, and to understand if it is safe for people.

Study Details

Full Title
A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO)
Principal Investigator
General Surgeon
Protocol Number
IRB: PRO00086917
NCT: NCT03663712
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698